Article révisé par les pairs
Titre:
  • A Phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors
Auteur:Angevin, Eric; Tabernero, Josep; Elez, Elena; Cohen, Steven; Bahleda, Rastilav; Van Laethem, Jean-Luc; Ottensmeier, Christian; Lopez-Martin, Jose J.A.; Clive, Sally; Joly, Florence; Ray-Coquard, Isabelle; Dirix, Luc Y; Machiels, Jean-Pascal; Steven, Neil; Reddy, Manjula; Hall, Brett; Puchalski, Thomas T.A.; Bandekar, Rajesh; Van De Velde, Helgi; Tromp, Brenda; Vermeulen, Jessica; Kurzrock, Razelle
Informations sur la publication:Clinical cancer research, 20, 8, page (2192-2204)
Statut de publication:Publié, 2014-04
Sujet CREF:Cancérologie
MeSH keywords:Adult
Aged
Animals
Antibodies, Monoclonal -- adverse effects -- pharmacokinetics -- therapeutic use
Area Under Curve
CHO Cells
Cricetinae
Cricetulus
Dose-Response Relationship, Drug
Fatigue -- chemically induced
Female
Humans
Interleukin-6 -- immunology
Liver -- drug effects -- physiopathology
Male
Metabolic Clearance Rate
Middle Aged
Mutation
Nausea -- chemically induced
Neoplasms -- drug therapy -- genetics -- metabolism
Neutropenia -- chemically induced
Proto-Oncogene Proteins -- genetics
Treatment Outcome
ras Proteins -- genetics
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1078-0432
info:doi/10.1158/1078-0432.CCR-13-2200
info:pii/1078-0432.CCR-13-2200
info:scp/84898967209
info:pmid/24563479

Documents en relation

DI-fusion